Hence, an anti-DENV vaccine based on NS proteins that can activate such cells, are safer and more prone to induce cross-reactive protective immunity against primary dengue infection and to prevent pathogenic effects of sub-neutralizing antibodies during heterologous DENV serotype infection. Here, KRAS is linked to infection.